LON:DOCS Dr. Martens (DOCS) Share Price, News & Analysis GBX 76.80 +2.60 (+3.50%) As of 12:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Dr. Martens Stock (LON:DOCS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dr. Martens alerts:Sign Up Key Stats Today's Range 69.90▼ 77.2050-Day Range 60.70▼ 76.8052-Week Range 59.15▼ 100.87Volume2.20 million shsAverage Volume8.23 million shsMarket Capitalization£735.06 millionP/E Ratio32.00Dividend Yield3.57%Price TargetGBX 105Consensus RatingModerate Buy Company Overview Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index. Dr. Martens operates across three geographic regions: EMEA, Americas and APAC. Our product segments include Originals, Fusion, Kids and Casual and a complementary range of Accessories. Read More Dr. Martens Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreDOCS MarketRank™: Dr. Martens scored higher than 86% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingDr. Martens has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialDr. Martens has a consensus price target of GBX 105, representing about 36.7% upside from its current price of GBX 76.80.Amount of Analyst CoverageDr. Martens has only been the subject of 2 research reports in the past 90 days.Read more about Dr. Martens' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Martens is 32.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Martens is 32.00, which means that it is trading at a less expensive P/E ratio than the Consumer Cyclical sector average P/E ratio of about 77.38.Price to Earnings Growth RatioDr. Martens has a PEG Ratio of 6.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Martens has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DOCS. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipDr. Martens is a leading dividend payer. It pays a dividend yield of 3.57%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthDr. Martens does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Martens is 106.25%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Dr. Martens' dividend. News and Social Media2.3 / 5News SentimentN/A News SentimentDr. Martens has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Consumer Cyclical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Dr. Martens this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for DOCS on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Dr. Martens in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net £220,614.08 in company stock, which represents 0.0300% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Dr. Martens insiders have bought more of their company's stock than they have sold. Specifically, they have bought £220,614.08 in company stock and sold GBX 0 in company stock.Percentage Held by Insiders2.94% of the stock of Dr. Martens is held by insiders.Percentage Held by Institutions19.06% of the stock of Dr. Martens is held by institutions.Read more about Dr. Martens' insider trading history. Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Martens and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DOCS Stock News HeadlinesUK's Dr Martens backs annual outlook on US wholesale demandJuly 15 at 12:11 AM | msn.comDr. Martens Adds New Shares to LSE Under Employee SchemesJune 30, 2026 | tipranks.comJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI breakthrough they call 'M.A.G.I.' will collide with a rare market pattern by July 30. That pattern carries a 100% historical track record. The last time it triggered, early investors had a chance to turn $10,000 into as much as $350,000 in roughly 12 months.July 16 at 1:00 AM | Brownstone Research (Ad)Dr. Martens Sets Total Voting Rights at 967.97 Million SharesJune 30, 2026 | tipranks.comDr. Martens (LON:DOCS) Insider Buys 68,313 Shares of StockJune 27, 2026 | insidertrades.comDr. Martens (LON:DOCS) Insider Buys £149.48 in StockJune 17, 2026 | insidertrades.comDr. Martens CEO boosts stake with six-figure share purchaseJune 16, 2026 | tipranks.comDr. Martens Links Executive Pay to Long-Term Performance With New Share AwardsJune 2, 2026 | tipranks.comSee More Headlines DOCS Stock Analysis - Frequently Asked Questions How have DOCS shares performed this year? Dr. Martens' stock was trading at GBX 76.60 on January 1st, 2026. Since then, DOCS stock has increased by 0.3% and is now trading at GBX 76.80. How were Dr. Martens' earnings last quarter? Dr. Martens plc (LON:DOCS) announced its quarterly earnings data on Tuesday, May, 19th. The company reported $4.20 earnings per share for the quarter. The business had revenue of $764.90 million for the quarter. Dr. Martens had a trailing twelve-month return on equity of 6.89% and a net margin of 3.11%. Read the conference call transcript. How do I buy shares of Dr. Martens? Shares of DOCS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Dr. Martens own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Martens investors own include boohoo group (BOO), Aston Martin Lagonda Global (AML), ASOS (ASC), Vodafone Group Public (VOD), JD Sports Fashion (JD), Legal & General Group (LGEN) and Lloyds Banking Group (LLOY). Company Calendar Last Earnings5/19/2026Today7/16/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorConsumer Cyclical Industry Footwear & Accessories Sub-IndustryComputer Software Current SymbolLON:DOCS CIKN/A Webwww.drmartensplc.com Phone44 12 1415 7047FaxN/AEmployees890Year FoundedN/APrice Target and Rating Average Price Target for Dr. MartensGBX 105 High Price TargetGBX 110 Low Price TargetGBX 100 Potential Upside/Downside+36.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)GBX 2.40 Trailing P/E Ratio32.00 Forward P/E Ratio29.76 P/E Growth6.4Net Income£68.97 million Net Margins3.11% Pretax MarginN/A Return on Equity6.89% Return on Assets8.12% Debt Debt-to-Equity Ratio108.85 Current Ratio2.61 Quick Ratio1.13 Sales & Book Value Annual Sales£764.90 million Price / Sales0.96 Cash FlowGBX 5.38 per share Price / Cash Flow14.29 Book ValueGBX 37.80 per share Price / Book2.03Miscellaneous Outstanding Shares957,113,000Free FloatN/AMarket Cap£735.06 million OptionableNot Optionable Beta0.25 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (LON:DOCS) was last updated on 7/16/2026 by MarketBeat.com Staff. From Our PartnersWhat Saudi Arabia just did to the dollar changes everythingIn June 2024, a 50-year arrangement tying Saudi oil to the U.S. dollar quietly expired. Garrett Goggin, CFA, C...Golden Portfolio | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredVWAV: Is This the Next Defense Breakout?VisionWave Holdings (NASDAQ: VWAV) is developing a full-stack defense technology platform integrating AI, RF s...Equiscreen | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredAI investors should get ready for a BIG surpriseWall Street insider Jason Bodner - who called Nvidia at $4.50 - says today's most popular AI stocks are about ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Martens plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Martens With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
